核苷酸适体在靶向给药系统中的应用进展

熊叶; 台宗光; 李强

doi:10.3969/j.issn.1006-0111.2015.06.003

核苷酸适体在靶向给药系统中的应用进展

doi: 10.3969/j.issn.1006-0111.2015.06.003

1.
第二军医大学附属长海医院, 上海 200433
2.
第二军医大学附属长海医院, 上海 200433;解放军92330部队医院, 山东青岛 266102

基金项目: 国家自然科学基金项目(No.81170060)

Application progress of nucleic acid aptamers in targeted drug delivery system

1.
Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China
2.
Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China;Hospital of CPLA No.92330 Troop, Qingdao 266102, China

摘要: 适体,即体外合成筛选得到的能特异性地与靶分子结合的一段寡核苷酸序列。由于其独特的性质,在靶向给药系统中有着广阔的应用前景,目前已成为靶向给药研究领域的热点。综述了适体在靶向给药系统中的优势及其应用进展,并对其应用前景和面临的问题进行分析。
- 核苷酸适体 /
- 靶向给药 /
- 应用进展
Abstract: Aptamers are single stranded oligonucleotides that have high affinity and specificity towards a wide range of target molecules. Owing to the indispensable advantages, aptamers have wildly prospects and have become a research hotspot in targeted drug delivery system (TDDS). In this article, application advantage and progress of aptamers in TDDS were briefly reviewed, the problems and prospects were also discussed.
- nucleic acid aptamers /
- targeted drug delivery /
- application progress

[1]	Tan W, Wang H, Chen Y, et al. Molecular aptamers for drug delivery[J]. Trends Biotechnol, 2011, 29(12): 634-640.
[2]	Ozalp VC, Eyidogan F, Oktem HA. Aptamer-gated nanoparticles for smart drug delivery[J]. Pharmaceuticals, 2011, 4(8): 1137-1157.
[3]	Taouji S, Dausse E, Evadé L, et al. Advances in binder identification and characterisation: the case of oligonucleotide aptamers[J]. N Biotechnol, 2012, 29(5): 550-554.
[4]	Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy[J]. Chem Rev, 2007, 107(9): 3715-3743.
[5]	Lupold SE, Hicke BJ, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen[J]. Cancer Res, 2002, 62(14): 4029-4033.
[6]	Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates a new approach for targeting prostate cancer cells[J]. Cancer Res, 2004, 64(21): 7668-7672.
[7]	Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform[J]. Angew Chem Int Ed, 2006, 45(48): 8149-8152.
[8]	Kraus E, James W, Barclay AN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function[J]. J Immunol, 1998, 160(11): 5209-5212.
[9]	Guo S, Tschammer N, Mohammed S, et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA[J]. Hum Gene Ther, 2005, 16(9): 1097-1110.
[10]	Khaled A, Guo S, Li F, et al. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology[J]. Nano Lett, 2005, 5(9): 1797-1808.
[11]	Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands[J]. Cell Signal, 2005, 17(10): 1183-1193.
[12]	Li N, Larson T, Nguyen HH, et al. Directed evolution of gold nanoparticle delivery to cells[J]. Chem Commun, 2010, 46(3): 392-394.
[13]	Prebet T, Lhoumeau A-C, Arnoulet C, et al. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome[J]. Blood, 2010, 116(13): 2315-2323.
[14]	Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study[J]. P Natl Acad Sci USA, 2006, 103(32): 11838-11843.
[15]	Xiao Z, Shangguan D, Cao Z, et al. Cell-specific internalization study of an aptamer from whole cell selection[J]. Chem Eur J, 2008, 14(6): 1769-1775.
[16]	Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells[J]. Chem Bio Chem, 2009, 10(5): 862-868.
[17]	o'donoghue MB. A liposome-based nanostructure for aptamer directed delivery[J]. Chem Commun, 2010, 46(2): 249-251.
[18]	胡萍. 肿瘤发生和 MUC1 及 Survivin 研究进展[J]. 中国医药指南, 2013, 11(1): 69-70.
[19]	Altschuler Y, Kinlough CL, Poland PA, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state[J]. Mol Biol Cell, 2000, 11(3): 819-831.
[20]	Gendler SJ. MUC1, the renaissance molecule[J]. J Mammary Gland Biol Neoplasia, 2001, 6(3): 339-353.
[21]	Ferreira CS, Cheung MC, Missailidis S, et al. Phototoxic aptamers selectively enter and kill epithelial cancer cells[J]. Nucleic Acids Res, 2009, 37(3): 866-876.
[22]	Do Kwon Y, Finzi A, Wu X, et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops[J]. P Natl Acad Sci USA, 2012, 109(15): 5663-5668.
[23]	Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy[J]. Mol Ther, 2008, 16(8): 1481-1489.
[24]	Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism[J]. Cancer Res, 2010, 70(21): 8617-8629.
[25]	Cao Z, Tong R, Mishra A, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes[J]. Angew Chem Int Ed, 2009, 48(35): 6494-6498.
[26]	胡艳玲, 史爱欣, 傅得兴, 等. 哌加他尼钠的药理作用和临床评价[J]. 中国新药杂志, 2007, 16(7): 573-576.
[27]	Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy[J]. Graef Arch Clin Exp, 2010, 248(7): 915-930.
[28]	Proske D, Gilch S, Wopfner F, et al. Prion-protein-specific aptamer reduces PrPSc formation[J]. Chem Bio Chem, 2002, 3(8): 717-725.
[29]	Jeon SH, Kayhan B, Ben-Yedidia T, et al. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin[J]. J Biol Chem, 2004, 279(46): 48410-48419.
[30]	Becker RC, Chan MY. REG-1, a regimen comprising RB-006, a Factor Ⅸa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis[J]. Curr Opin Mol Ther, 2009, 11(6): 707-715.

[1]	冯婷婷, 张景翔, 王彦, 许维恒, 张俊平. ANXA3基因及蛋白的研究进展 . 药学实践与服务, 2025, 43(2): 47-50, 74. doi: 10.12206/j.issn.2097-2024.202309023
[2]	刘梦肖, 陈林林, 王彦, 张俊平. 中药苦参的研究进展 . 药学实践与服务, 2025, 43(4): 156-162. doi: 10.12206/j.issn.2097-2024.202406053
[3]	游飘雪, 陈兰, 施艺玮, 王辉, 晁亮, 洪战英. 脑胶质瘤微流控芯片模型的构建及中药半枝莲药效评价应用研究 . 药学实践与服务, 2025, 43(2): 59-66. doi: 10.12206/j.issn.2097-2024.202409034
[4]	魏莱, 董国强, 盛春泉. 靶向SARS-CoV-2主蛋白酶的PROTAC设计、合成与蛋白降解活性研究 . 药学实践与服务, 2025, 43(5): 1-8. doi: 10.12206/j.issn.2097-2024.202503063
[5]	刘桂株, 李行, 王楠, 王芳, 胡旭, 汤佳洁. 信息技术在我国用药安全领域应用的计量分析 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202303027
[6]	王晓飞, 张颖, 顾佳钰, 胡馨儿, 张海, 曹岩. 表面等离子共振传感器的识别元件在医药领域中的研究应用进展 . 药学实践与服务, 2025, 43(5): 1-9. doi: 10.12206/j.issn.2097-2024.202309014
[7]	吴海韵, 杨甜, 张弛, 梁文仪, 苏娟. 气相色谱-离子迁移谱技术在中药研究中的应用进展 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202409007
[8]	冯一帆, 严啸东, 张文彬, 李炳锋, 郭美丽. 菸花苷长期给药对脑缺血再灌注损伤大鼠神经功能的影响 . 药学实践与服务, 2025, 43(5): 1-7. doi: 10.12206/j.issn.2097-2024.202407038
[9]	魏雨辰, 田家盛, 王道鑫, 凌期盛, 王治, 缪朝玉. 烟酰胺单核苷酸口服给药对高血压大鼠的影响 . 药学实践与服务, 2025, 43(5): 1-9. doi: 10.12206/j.issn.2097-2024.202412006
[10]	张广雨, 杜晶, 刘梦珍, 朱丹妮, 闫慧, 刘冲. 新斯的明与山莨菪碱联合应用对肺型氧中毒的保护作用及其机制的研究 . 药学实践与服务, 2024, 42(10): 433-438, 444. doi: 10.12206/j.issn.2097-2024.202310049
[11]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
[12]	何亚伦, 祁智, 常杰. 消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
[13]	刘依秦, 王超群, 邱娇娜. 胆宁片预处理在糖尿病患者结肠镜检查前的应用效果分析 . 药学实践与服务, 2024, 42(9): 407-410. doi: 10.12206/j.issn.2097-2024.202407037
[14]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[15]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[16]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[17]	陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠. UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082
[18]	张林晨, 张小琴, 张俊平. 山楂酸药理作用的研究进展 . 药学实践与服务, 2024, 42(5): 185-189. doi: 10.12206/j.issn.2097-2024.202307052
[19]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
[20]	杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯. 瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026

点击查看大图

计量

文章访问数: 3924
HTML全文浏览量: 330
PDF下载量: 292
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

核苷酸适体在靶向给药系统中的应用进展

doi: 10.3969/j.issn.1006-0111.2015.06.003

Application progress of nucleic acid aptamers in targeted drug delivery system

计量

核苷酸适体在靶向给药系统中的应用进展

doi: 10.3969/j.issn.1006-0111.2015.06.003

1. 第二军医大学附属长海医院, 上海 200433

2. 第二军医大学附属长海医院, 上海 200433;解放军92330部队医院, 山东青岛 266102

English Abstract

Application progress of nucleic acid aptamers in targeted drug delivery system

1. Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

2. Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China;Hospital of CPLA No.92330 Troop, Qingdao 266102, China

全文HTML

目录

留言板

核苷酸适体在靶向给药系统中的应用进展

doi: 10.3969/j.issn.1006-0111.2015.06.003

Application progress of nucleic acid aptamers in targeted drug delivery system

计量

出版历程

核苷酸适体在靶向给药系统中的应用进展

doi: 10.3969/j.issn.1006-0111.2015.06.003

1. 第二军医大学附属长海医院, 上海 200433 2. 第二军医大学附属长海医院, 上海 200433;解放军92330部队医院, 山东 青岛 266102

English Abstract

Application progress of nucleic acid aptamers in targeted drug delivery system

1. Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China 2. Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China;Hospital of CPLA No.92330 Troop, Qingdao 266102, China

全文HTML

目录

1. 第二军医大学附属长海医院, 上海 200433

2. 第二军医大学附属长海医院, 上海 200433;解放军92330部队医院, 山东青岛 266102

1. Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

2. Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China;Hospital of CPLA No.92330 Troop, Qingdao 266102, China